Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Bridget Silverman
From 'breakthrough' designations to manufacturing hiccups, numerous review and development challenges await the combined entity.
Aimovig, Andexxa, Lucemyra, and pegvaliase are among the almost 20 products with upcoming user fee goals at US FDA this month.